For decades, vaccine development has largely been a race against time. Scientists identify a virus, study its mutations and work to produce a vaccine before the pathogen gains ground.
Researchers at the University of Cambridge believe they may have found a way to change that equation.
In what scientists describe as a world-first achievement, a vaccine designed using artificial intelligence has been tested in humans, marking a significant step towards creating vaccines that could protect against entire families of viruses rather than a single strain.
The experimental vaccine targets coronaviruses, a broad group of viruses that includes COVID-19 and several animal-borne viruses that could potentially spark future outbreaks.
The early-stage research, published in the Journal of Infection, involved 39 participants and was primarily designed to assess safety. While the immune response observed so far has been described as modest, researchers say the results offer an encouraging glimpse into a different approach to pandemic preparedness.
“We’re always behind,” said Professor Jonathan Heeney of the University of Cambridge, who is leading the research. “What we’re trying to do is get ahead of the curve.”
Unlike conventional vaccines, which are typically built around a virus currently circulating among humans, the Cambridge team fed genetic information from a wide range of known coronaviruses into an artificial intelligence system. The technology analysed the data and produced a synthetic antigen, the component of a vaccine that teaches the immune system what to recognise and attack.
The aim was not to prepare the body for one specific virus, but for a much wider group of related threats, including strains that may emerge in the future.
“This is about making vaccines that protect us, not just from today’s viruses, but from those that could cause the next outbreak,” Professor Heeney said. “It’s a fundamental shift in how we prepare for pandemics.”
Researchers say this is the first time a vaccine component designed entirely by artificial intelligence has advanced to human testing.
The work remains at an early stage. A larger study involving roughly 200 participants is now underway to provide a clearer picture of how effectively the vaccine stimulates immune defences.
Independent experts have welcomed the findings while urging caution.
Professor Saul Faust of the University of Southampton, who was involved in parts of the clinical testing, said the technology showed promise, particularly because viruses evolve constantly.
“What’s really interesting is that the technology appears better suited to designing vaccines for viruses that keep changing,” he said.
The Cambridge researchers are already exploring whether the same approach could be used to develop a universal flu vaccine, eliminating the need for annual reformulation. They are also investigating vaccines against H5N1 bird flu and viral haemorrhhagic fevers, including Ebola.
The latter remains a pressing concern in parts of Africa, where outbreaks continue to pose serious public health challenges.
Professor Andy Pollard, director of the Oxford Vaccine Group, who was not involved in the study, described the results as intriguing. However, he noted that success in laboratory settings does not always translate into success in people.
“It’s fascinating data,” he said. “The real test is what happens in human trials because human immune systems are shaped by years of exposure to infections and are much more complex than those of laboratory animals.”
Still, many researchers believe artificial intelligence could significantly speed up vaccine development by helping scientists predict how the immune system may respond to potential vaccine candidates.
Professor Marian Knight, scientific director at the National Institute for Health and Care Research, said the study highlighted the growing potential of combining advanced computing with medical science.
“The success of this trial represents an important step towards broader and longer-lasting protection against viral diseases,” she said.
Whether the technology ultimately delivers on its promise remains to be seen. Larger studies and years of further research lie ahead.
But after a pandemic that exposed the world’s vulnerability to emerging diseases, scientists are increasingly looking beyond reacting to outbreaks and towards preventing them before they begin.
About the Author
